Ingersoll-rand (ireland) Stock Earnings Reports

Ingersoll Rand reported a generally steady Q3 2025 with disciplined execution amid a dynamic macro environment. Key operational points: organic orders up modestly (year-to-date +2%; Q3 organic orders +2% company-wide; ITS and PST showing low-single-digit organic order growth), book-to-bill around 1.04x YTD, and backlog up high-teens since end-2024. Q3 adjusted EBITDA was $545M (27.9% margin); adjusted EPS $0.86 (up 2% YoY). Free cash flow was $326M in the quarter and liquidity remains strong at ~$3.8B; leverage ~1.8x. Capital deployment included $249M M&A, $193M share repurchases (approx. 2.5M shares), and $8M dividends in the quarter. M&A remains a core strategy: 14 deals closed YTD, 9 LOIs, bolt-ons averaging ~9.5x pre-synergy multiples, and a stated target of adding 400–500 bps of inorganic revenue annually. PST showed solid margin improvement (30.8% Q3) and life sciences wins; ITS highlighted product innovation (META compressor) but faced temporary margin dilution from tariffs. Management updated 2025 guidance: revenue and organic volume views unchanged; midpoint of adjusted EBITDA guidance moderated to $2.075B and adjusted EPS midpoint lowered to $3.28 (from $3.40) primarily due to incremental tariffs and timing of price realization from backlog. Management expects pricing actions to offset tariffs but timing will push full realization into 2026; the company also implemented proactive cost actions (largely headcount-related) that will have more effect in 2026. They remain confident in long-term investor-day margin targets (ITS ~30% by 2027; PST mid-30s) and continue to balance bolt-on M&A with opportunistic buybacks.